Cargando…
Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis
Hepatitis B virus (HBV) is a major pathogen that causes acute/chronic hepatitis. Continuous HBV infection can lead to the development of hepatocellular carcinoma (HCC). Although several different anti-HBV treatments are available for chronic hepatitis B patients, discontinuing these medications is d...
Autores principales: | Ouchida, Tsunenori, Takamatsu, Shinji, Maeda, Megumi, Asuka, Tatsuya, Morita, Chiharu, Kondo, Jumpei, Ueda, Keiji, Miyoshi, Eiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473023/ https://www.ncbi.nlm.nih.gov/pubmed/34578441 http://dx.doi.org/10.3390/v13091860 |
Ejemplares similares
-
The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro
por: Ouchida, Tsunenori, et al.
Publicado: (2023) -
Vesicular Integral-Membrane Protein 36 Is Involved in the Selective Secretion of Fucosylated Proteins into Bile Duct-like Structures in HepG2 Cells
por: Muranaka, Mizuki, et al.
Publicado: (2023) -
Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD
por: Kamada, Yoshihiro, et al.
Publicado: (2022) -
GlycoBioinformatics
por: Aoki-Kinoshita, Kiyoko F, et al.
Publicado: (2021) -
Transcription factor SP1 regulates haptoglobin fucosylation via induction of GDP-fucose transporter 1 in the hepatoma cell line HepG2
por: Kondo, Jumpei, et al.
Publicado: (2022)